@article{d16dbd821c8249c6a2bbfcd7a2bc5b2d,
title = "Characterisation of age and polarity at onset in bipolar disorder",
abstract = "Background Studying phenotypic and genetic characteristics of age at onset (AAO) and polarity at onset (PAO) in bipolar disorder can provide new insights into disease pathology and facilitate the development of screening tools. Aims To examine the genetic architecture of AAO and PAO and their association with bipolar disorder disease characteristics. Method Genome-wide association studies (GWASs) and polygenic score (PGS) analyses of AAO (n = 12 977) and PAO (n = 6773) were conducted in patients with bipolar disorder from 34 cohorts and a replication sample (n = 2237). The association of onset with disease characteristics was investigated in two of these cohorts. Results Earlier AAO was associated with a higher probability of psychotic symptoms, suicidality, lower educational attainment, not living together and fewer episodes. Depressive onset correlated with suicidality and manic onset correlated with delusions and manic episodes. Systematic differences in AAO between cohorts and continents of origin were observed. This was also reflected in single-nucleotide variant-based heritability estimates, with higher heritabilities for stricter onset definitions. Increased PGS for autism spectrum disorder (β = −0.34 years, s.e. = 0.08), major depression (β = −0.34 years, s.e. = 0.08), schizophrenia (β = −0.39 years, s.e. = 0.08), and educational attainment (β = −0.31 years, s.e. = 0.08) were associated with an earlier AAO. The AAO GWAS identified one significant locus, but this finding did not replicate. Neither GWAS nor PGS analyses yielded significant associations with PAO. Conclusions AAO and PAO are associated with indicators of bipolar disorder severity. Individuals with an earlier onset show an increased polygenic liability for a broad spectrum of psychiatric traits. Systematic differences in AAO across cohorts, continents and phenotype definitions introduce significant heterogeneity, affecting analyses.",
keywords = "Age at onset, Bipolar disorder, GWAS, Polarity at onset, Polygenic score",
author = "Kalman, {Janos L.} and {Olde Loohuis}, {Loes M.} and Annabel Vreeker and Andrew McQuillin and Stahl, {Eli A.} and Douglas Ruderfer and Maria Grigoroiu-Serbanescu and Georgia Panagiotaropoulou and Stephan Ripke and Bigdeli, {Tim B.} and Frederike Stein and Tina Meller and Susanne Meinert and Helena Pelin and Fabian Streit and Sergi Papiol and Adams, {Mark J.} and Rolf Adolfsson and Kristina Adorjan and Ingrid Agartz and Aminoff, {Sofie R.} and Heike Anderson-Schmidt and Andreassen, {Ole A.} and Raffaella Ardau and Aubry, {Jean Michel} and Ceylan Balaban and Nicholas Bass and Baune, {Bernhard T.} and Frank Bellivier and Antoni Benabarre and Susanne Bengesser and Berrettini, {Wade H.} and Boks, {Marco P.} and Bromet, {Evelyn J.} and Katharina Brosch and Monika Budde and William Byerley and Pablo Cervantes and Catina Chillotti and Sven Cichon and Clark, {Scott R.} and Comes, {Ashley L.} and Aiden Corvin and William Coryell and Nick Craddock and Craig, {David W.} and Croarkin, {Paul E.} and Cristiana Cruceanu and Kahn, {Rene S.} and Ophoff, {Roel A.}",
note = "Funding Information: Amare T. Azmeraw: has received 2020–2022 NARSAD Young Investigator Grant from the Brain & Behaviour Research Foundation. Ole A. Andreassen: speaker{\textquoteright}s honorarium Sunovion, Lundbeck. Consultant HealthLytix. Bernhard Baune: Honoraria: Lundbeck, Janssen, LivaNova, Servier. Carrie Bearden: Novartis Scientific Advisory Board. Clark Scott: Honoraria and Investigator-initiated project funding from Jannsen-Cilag Australia, Lundbeck-Otsuka Australia. J. Raymond DePaulo: owns stock in CVS Health; JRD was unpaid consultant for Myriad Neuroscience 2017 & 2019. Michael C. O´Donovan: research unrelated to this manuscript supported by a collaborative research grant from Takeda Pharmaceuticals. Bruno Etain: honoraria for Sanofi. Mark A. Frye: grant Support Assurex Health, Mayo Foundation, Medibio Consultant (Mayo) Actify Neurotherapies, Allergan, Intra-Cellular Therapies, Inc., Janssen, Myriad, Neuralstem Inc., Sanofi, Takeda, Teva Pharmaceuticals. Per Hoffmann: employee of Life&Brain GmbH, Member of the Scientific Advisory Board of HMG Systems Engeneering GmbH. Mikael Landen: Speaker{\textquoteright}s honoraria Lundbeck pharmaceuticals. Andrew M McIntosh: research funding from The Sackler Trust, speaker fees from Illumina and Janssen. Philip B. Mitchell: remuneration for lectures in China on bipolar disorder research by Sanofi (Hangzhou). John Nurnberger: investigator for Janssen. Benjamin M. Neale: is a member of the scientific advisory board at Deep Genomics and RBNC Therapeutics. A consultant for Camp4 Therapeutics, Takeda Pharmaceutical and Biogen. Andreas Reif: apeaker{\textquoteright}s honoraria / Advisory boards: Janssen, Shire/Takeda, Medice, SAGE and Servier. Eli Stahl: now employed by the Regeneron Genetics Center. Kato Tadafumi: honoraria: Kyowa Hakko Kirin Co., Ltd., Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Taisho Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd., Pfizer Japan Inc., Mochida Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Janssen Pharmaceutical K.K., Janssen Asia Pacific, Yoshitomiyakuhin, Astellas Pharma Inc., Nippon, Boehringer Ingelheim Co. Ltd., MSD K.K., Kyowa Pharmaceutical Industry Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Eisai Co., Ltd. Grants: Takeda Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation. Thomas G. Schulze: is a member of the editorial board of The British Journal of Psychiatry. He did not take part in the review or decision-making process of this paper. Eduard Vieta: has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage, Sanofi-Aventis, Sunovion and Takeda. None of the other authors reported any biomedical financial interests or potential conflicts of interest. ICMJE forms are in the supplementary material, available online at https://doi.org/10.1192/10.1192/bjp.2021.102. Publisher Copyright: Copyright {\textcopyright} The Author(s), 2021.",
year = "2021",
month = dec,
day = "11",
doi = "10.1192/bjp.2021.102",
language = "English",
volume = "219",
pages = "659--669",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "6",
}